Long-Term Prognosis and Transition Period until Progression in Fibrotic Hypersensitivity Pneumonitis
Respiration · 17.11.2026 · 105 (10) · 1063-1073
DOI: 10.1159/000551084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, online erschienen am 05.03.2026. Verfasst von María Florencia Pilia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Alveolitis, Extrinsic Allergic, Pulmonary Fibrosis. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Introduction
Hypersensitivity pneumonitis (HP) is an interstitial lung disease that may present as fibrotic (fHP) or non-fibrotic (nfHP). Fibrosis is associated with progression and poor outcomes; however, the transition to progressive pulmonary fibrosis (PPF) and its predictors remain unclear.
Methods
We retrospectively reviewed adult patients diagnosed with HP at a tertiary hospital (2010 and 2022). Patients were classified as having fHP or nfHP and were followed up for at least 1 year. Clinical, functional, radiological, and histological variables were analyzed. PPF was defined according to the 2022 clinical practice guideline of the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Asociación Latinoamericana de Tórax (ALAT).
Results
Of 298 HP patients, 191 were included (153 fHP and 38 nfHP). Among patients with fHP, 76 (49.7%) developed PPF after a median of 3.2 years. Median survival was 4.8 years in fHP with PPF versus 6.3 years without, with 1.6 years from PPF onset to death or transplantation. The independent predictors of PPF and survival were lower forced vital capacity, elevated lactate dehydrogenase, fibroblastic foci, and microscopic honeycombing.
Conclusion
Nearly half of fHP patients progressed to PPF within a few years, with markedly reduced survival. Early recognition of high-risk patients may support timely antifibrotic treatment and improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Pulmonology Department, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
- Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
- Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Pilia, M. F., Espejo, D., Sansano, I., Romero, C., Andreu-Casas, M., Ferreiro-Posse, A., Villar, A., Cruz, M. J., Muñoz, X., & Ojanguren, I. (2026). Long-Term Prognosis and Transition Period until Progression in Fibrotic Hypersensitivity Pneumonitis. Respiration, 105(10), 1063-1073. https://doi.org/10.1159/000551084
Vancouver
Pilia MF, Espejo D, Sansano I, Romero C, Andreu-Casas M, Ferreiro-Posse A, et al. Long-Term Prognosis and Transition Period until Progression in Fibrotic Hypersensitivity Pneumonitis. Respiration. 2026;105(10):1063-1073. doi:10.1159/000551084
BibTeX
@article{Pilia2026,
author = {Pilia, María Florencia and Espejo, David and Sansano, Irene and Romero, Christian and Andreu-Casas, Marta and Ferreiro-Posse, Antia and Villar, Ana and Cruz, María Jesús and Muñoz, Xavier and Ojanguren, Iñigo},
title = {Long-Term Prognosis and Transition Period until Progression in Fibrotic Hypersensitivity Pneumonitis},
journal = {Respiration},
year = {2026},
volume = {105},
number = {10},
pages = {1063--1073},
doi = {10.1159/000551084}
}
EUVIMED